Rinvoq
AbbVie announces first patient dosed in phase 3 trial of upadacitinib in hidradenitis suppurativa
July 25, 2023Research and Development AbbVie, Dermatology, HS, Rinvoq, clinical trial, upadacitinib
AbbVie has announced that the first patient has been dosed in its phase 3 Step-Up trial assessing Rinvoq (upadacitinib) for …
AbbVie’s Rinvoq hits target in psoriatic arthritis sub-population at Phase 3
February 6, 2020Research and Development AbbVie, Rinvoq, pharma, psoriatic arthritis
AbbVie has unveiled new Phase 3 data on its selective and reversible JAK inhibitor Rinvoq (upadacitinib) in the treatment of …
New ICER report reveals most cost-effective rheumatoid arthritis therapies
November 27, 2019Research and Development, Sales and Marketing AbbVie, Eli Lilly, Humira, Olumiant, Pfizer, Rinvoq, Xeljanz, pharma
The Institute for Clinical and Economic Review (ICER) has unveiled a new report comparing the clinical efficacy and cost-effectiveness of …
AbbVie’s Rinvoq impresses at Phase 3 in active psoriatic arthritis sub-population
October 31, 2019Research and Development AbbVie, Rinvoq, pharma
AbbVie has unveiled new Phase 3 data on two doses of its JAK inhibitor Rinvoq (upadacitinib), showing that the therapy …
AbbVie scoops up FDA approval for Rinvoq in moderately to severely active rheumatoid arthritis
August 19, 2019Sales and Marketing AbbVie, FDA, Rinvoq, pharma, rheumatoid arthritis
The FDA has awarded marketing authorisation to AbbVie’s Rinvoq (upadacitinib) for the treatment of moderately to severely active rheumatoid arthritis, …
Latest content
FibroFind appoints Lee Borthwick as CEO
July 21, 2026
